Bristol Myers posts quarterly loss, lays out $1.5 bln cost-saving plan
Bristol Myers Squibb reported a first-quarter loss on Thursday as charges related to its acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a small increase in revenue, sending shares down nearly 8%.